Enterprise Value

200.3M

Cash

79.93M

Avg Qtr Burn

-15.41M

Short % of Float

1.25%

Insider Ownership

42.02%

Institutional Own.

30.34%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PI-2620 Details
Neurological disorder, Alzheimer's disease

Phase 3

Data readout

ACI-35.030 (anti-pTau vaccine) or JACI-35.054 Details
Neurological disorder, Alzheimer's disease

Phase 2b

Data readout

ACI-7104.056 Details
Parkinson's disease

Phase 2

Data readout

Semorinemab Details
Neurological disorder, Alzheimer's disease

Phase 2

Data readout

Crenezumab Details
Alzheimer's disease, Neurological disorder

Phase 2

Update

ACI-24.060 (anti-Abeta vaccine) Details
Neurological disorder, Alzheimer's disease, Down Syndrome

Phase 1/2

Data readout

AC1-3024 Details
Neurological disorder

Failed

Discontinued